An inhibitor of adrenal steroid biosynthesis, aminoglutethimide, was administered to seven patients with low renin essential hypertension, and the antihypertensive action of the drug was compared with its effects on adrenal steroid production. In all patients aldosterone concentrations in plasma and urine were within normal limits before the study. Mean arterial pressure was reduced from a pretreatment value of 117±2 (mean±SE) mm Hg to 108±3 mm Hg after 4 days of aminoglutethimide therapy and further to 99±3 mm Hg when drug administration was stopped (usually 21 days). Body weight was also reduced from 81.6±7.2 kg in the control period to 80.6±7.0 kg after 4 days of drug treatment and to 80.1±6.7 kg at the termination of therapy. Plasma renin activity was not significantly increased after 4 days of treatment but had risen to the normal range by the termination of aminoglutethimide therapy. Mean plasma concentrations of deoxycorticosterone and cortisol were unchanged during aminoglutethimide treatment whereas those of 18-hydroxydeoxycorticosterone, progesterone, 17a-hydroxyprogesterone, and 11-deoxycortisol were increased as compared to pretreatment values. In contrast, aminoglutethimide treatment reduced mean plasma aldosterone concentrations to about 30% of control values. Excretion rates of 16b-hydroxydehydroepiandrosterone, 16-oxo-androstenediol, 17-hydroxycorticosteroids and 17-ketosteroids, and the secretion rate of 16b-hydroxydehydroepiandrosterone were not significantly altered by aminoglutethimide treatment whereas the excretion rate of aldosterone was reduced from 3. 62±0.5 (mean±SE) The gradual lowering of blood pressure and body weight during aminoglutethimide therapy is consistent with the view that the antihypertensive effect of the drug is mediated through a reduction in the patients' extracellular fluid volume, probably secondary to the persistent decrease in aldosterone production. The observation that chronic administration of aminoglutethimide lowered blood pressure in these patients and elevated their plasma renin activity to the normal range without decreasing production of the adrenal steroids, deoxycorticosterone, 18-hydroxydeoxycorticosterone, and 16,3-hydroxydehydroepiandrosterone, makes it unlikely that these steroids are responsible either for the decreased renin or the elevated blood pressure in patients with low renin essential hypertension.
A B S T R A C T An inhibitor of adrenal steroid biosynthesis, aminoglutethimide, was administered to seven patients with low renin essential hypertension, and the antihypertensive action of the drug was compared with its effects on adrenal steroid production. In all patients aldosterone concentrations in plasma and urine were within normal limits before the study. Mean The gradual lowering of blood pressure and body weight during aminoglutethimide therapy is consistent with the view that the antihypertensive effect of the drug is mediated through a reduction in the patients' extracellular fluid volume, probably secondary to the persistent decrease in aldosterone production. The observation that chronic administration of aminoglutethimide lowered blood pressure in these patients and elevated their plasma renin activity to the normal range without decreasing production of the adrenal steroids, deoxycorticosterone, 18-hydroxydeoxycorticosterone, and 16,3-hydroxydehydroepiandrosterone, makes it unlikely that these steroids are responsible either for the decreased renin or the elevated blood pressure in patients with low renin essential hypertension.
INTRODUCTION
Patients with hypertension and low plasma renin activity (PRA)' can be subdivided further into those with an elevated, normal, or reduced aldosterone excretion rate. Patients in the first category have primary aldosteronism (1) (2) (3) (4) (5) . The finding that low renin hypertension was present in 9-50% of hypertensive patients, depending upon the age of the population studied (6, 7), generated considerable interest in the pathophysiologic mechanisms which might contribute to a low plasma renin. The report by \VToods et al. (8) that aminoglutethimide, an inhibitor of adrenal steroid biosynthesis, normalized blood pressture in hypertensive patients wvith low PRA raised the possibility that these patients could be treated specifically. This possibility was supported by the finding that spironolactone, an antagonist of the renal action of aldosterone and other mineralocorticoid hormones, more effectively lowered blood pressure in patients with low vs. normal renin essential hypertension (9) . Because aldosterone production is not elevated in patients with low renin essential hypertension, an intensive search for a new sodium retaining steroid other than aldosterone was instituted. Subse(quently, increased secretion or excretion of deoxycorticosterone (DOC) (10), 18-hydroxydeoxycorticosterone (18-OH DOC) (11, 12) , and 16,3-hydroxydehydroepiandrosterone (16,B-OH DHEA) (13) has been reported in groups of patients with low renin hypertension as compared to groups of patients with normal renin hypertension or normotensive subjects. However, no cause-and-effect stuidies have been carried out to compare blood pressure changes and steroid secretion in the same patients. In the present study, therefore, the effect of aminogluitethimide on the production of selected adrenal steroids is compared directly with its antihypertensive effect in seven patients with low renin essential hypertension. (thl-ee) or their medicationis had been discontinued for at least 6 wk before the study (four).
METHODS
Protocol for a it inoglnttethli7oi(le adit iniistratioYi. The stuidy was approved by the clinical research review committee of the National Heart, Lung, and Blood Institute, and all patients gave written informed consent before participating in the study. The patients were hospitalized and given a daily diet containing 209 meq sodium to avoid stimulation of PRA. Urine was collected contintuously in 24-h aliquots for determinations of' creatiniine, sodium, potassiumil, 1 7-hvdroxycorticosteroids (170HCS), 17-ketosteroids (17KS) and aldosterone excretion rates. After overnight recumbency, blood was collected at 8 a.m. on the 3rd hospital day for PRA and f'or plasma steroids including aldosterone, progesterone, 17 a-hydroxyprogesterone, DOC, 18-OH DOC, 11-deoxvcortisol, and cortisol. Patients then stood until 12 noon at wlhich time blood was obtained f'or PRA and plasma steroids. Blood f'or measurement of'plasma steroids \vas obtained at 6 p.m. while posture was not controlled and again at 12 midnight and 6 a.m. after the patients had retired to bed at 10 p.m. Blood xvas collected in tubes containing disodium EDTA for PRA (17) by previously published methodls. PRA was measured at Hazletoni Laboratories, Vienna, Va., under contract no. 272-76-C-0641CC with the National Heart, Lung, and Blood Institute. The amount of' angiotensini I genierated during a 3-h incubationi at pH 6.4 was determinled by radioimmunoassav (18) .
Steroid mceastnreme nt.ss. Exeretioni of aldosterone-18-glueuronide was determined by radioimmunoassav, wvithout prior chromatography, after 24-h hydrolysis at pH 1 (19) . Plasma concentrations of aldosterone (20) , progesterone (21), 17a-hydroxyprogesterone (22) , cortisol,2 and 11-deoxycortisol2 were determined by radioimmunoas say at Hazleton Laboratories. Plasma deoxycorticosterone (19) (Fig. 1) . In contrast, mean values for the 35 plasma aldosterone determinations during treatment with aminoglutethimide were 30% of control values (3.4±0.6 vs. 10.5±1.0 ng/dl), and plasma aldosterone was often undetectable by the radioimmunoassay, the sensitivity of which was 2.5 ng/dl. Thus, only plasma aldosterone was decreased, whereas other plasma steroid concentrations remained unchanged or were increased during treatment with aminoglutethimide (Fig. 1) . These effects persisted throughout 21 days of aminoglutethimide therapy in the two patients who were restudied (Fig. 2) . Mean values for the 10 plasma cortisol samples (5 determinations each in the 2 patients) during the control period were not significantly dif- FIGuRE 2 Plasma concentrations of selected steroids in two patients with low renin essential hypertension before (control) and again 4 (26, 27) . The gradual lowering of' blood pressure an(d body weight during aminoglutethimide therapy in our low renin patients is also conisistent with the view that the antihypertenisive eff'ect of' the drug is mediated through a reduction in extracellular fluid volume, probably secondary to the sustained suppression of' aldosterone production (Table I) . Although aldosterone secretion rates were not measured in these patients, the finding that aminoglutethimide reduced both plasma aldosterone concentration and the urinary excretion of'the 18-glucuronide metabolite of' aldosterone strongly suipports a decrease in adrenal aldosterone production induced by the drug rather than an alteration in the extraadrenal metabolism of aldosterone by aminoglutethimide.
The secretion of aldosterone by the adrenal zona glomerulosa remains inhibited by aminoglutethimide even after months of' continuous therapy, and compenisatory increases in plasma renin do not overcome the inhibition (26) . In contrast, whereas secretion of cortisol and related steroids by the adrenal zona fasciculata is decreased by amiiinoglutethimide, the eff'ect is not sustained becauise the initial f'all in plasma cortisol concentration leads to a compensatory increase in ACTH release (26) (27) (28) . ACTH, in turn, stimulates the adrenal formation of A5-preginenolone f'rom cholesterol, the major step in steroid biosynthesis that is inhibited bv amiiinoglutethiimiide (27) . The increases in plasmiia Woncentrations of progesterone, 17 a-hydroxyprogesterone, li-deoxycortisol, and 18-OH DOC observed in our 7 patients after 4 days of' aminoglutethimi(le treatment and in 2 of'these patients after 21 days of'tlherapy probably reflects such a compensatory increase in ACTH because concentrations of plasma cortisol were maintained in spite of' clroniic administratioin of' amiinogluitethimide.
The observation that ami-inoglutethimide lowered bloo10 pressure in our patienits withouit decreasing the production of' the adrenal steroids, DOC, 18-OH DOC, anid 16,8-OH DHEA, makes it unlikely that these steroidls are involved in the pathogenesis of'low renin essential hypertension. Similarly, these steroids are apparently not responsible f'or the lowZ plasma renini activity in these patieints because their production is not dlecreased when PRA rises to the normal range during long-term treatment with aminioglutethimide (Fig. 2) . However, it remains to be determiinied if' an heretofore unidenitified adrenial steroid(s), or a steroid stuclh as 16 a, 18-dihydroxydeoxycorticosteronie whose secretion rate was not measured in this studv, miglht play ain etiologic role in the pathogenesis of low renin hypertension. It is more likely that one of' the steroids measuired in this study or an unidentified adrenocortical hormone is of pathogenetic importance in the small number of low renin patients who demiionstrate stubnormal aldosterone production; such patienits wvere not evaluated in the present study.
Additional evidence against the hypothesis that the secretion of'an unidentified sodiuim retaining steroid is responsible for the low PRA and elevated blood pressure in patienits witl low renini essential hypertenision is the normiial aldosteronie excretion rate present in almost all patients with low renin essential hypertension (5, 6, 29) . The normiial excretioni rate contrasts markedly to the decreased aldosteronie excretion seeni wvith states of' known-imineralocorticoid excess, such as congenital adrenal hyperplasia wvith 11,1-hydroxylase deficiency (30), or exogenous deoxycorticosterone administration (31) . The normal aldosterone excretion rate in patienits with low renin-essential hypertension results from anl increased aldosteronie response per unit of' renin (16, 29) . These patients also showz an exaggerated aldosterone response per unit of' infused angiotensin II, which suggests that the molecular abnormality is probably a stupersensitivity to angiotensin II at the adrenal receptor for aldosterone synthesis (16, 29) . It is not 166 Taylor, Mitchell, Bartter, Snodgrass, McMurtry, Gill, and Franiklin clear at present whether the supersensitivity to angiotensin II is a primary adrenal defect or whether it occurs in response to an abnormally low production of renin by the kidney with a secondary increase in adrenal receptor sensitivity similar to that seen in smooth muscle during denervation supersensitivity (32) .
It is also not clear why therapy with aminoglutethimide lowers blood pressure less in normal renin patients than in patients with low renin hypertension (8) . Maintenance of blood pressure, however, depends not only upon aldosterone-regulated changes in blood volume but also upon the direct vasoconstriction produced by angiotensin 11 (33) . Thus, administration of aminoglutethimide to patients with normal renin essential hypertension decreases their aldosterone production, and presumably their blood volume (8, 27) , but the rapid rise in renin and angiotensin II concentrations would be expected to lead to vasoconstriction, thereby compensating in part for the tendency towards reduced blood pressure secondary to the decrease in blood volume. In contrast, patients with low renin essential hypertension have low plasma concentrations of angiotensin 11 (34, 35) , and may be more dependent upon blood volume for maintenance of blood pressure. Thus, their hypertension might be expected to respond more readily to the antialdosterone actions of aminoglutethimide. A greater dependency of their blood pressure on volume rather than on vasoconstrictor factors might also explain the greater antihypertensive response to diuretic therapy of patients with low vs. normal renin essential hypertension (9) .
